{"id":13160,"date":"2024-07-08T19:18:58","date_gmt":"2024-07-08T17:18:58","guid":{"rendered":"https:\/\/q-finity.de\/?page_id=13160"},"modified":"2026-08-05T16:52:58","modified_gmt":"2026-08-05T14:52:58","slug":"computer-software-assurance","status":"publish","type":"page","link":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","title":{"rendered":"Computer Software Assurance"},"content":{"rendered":"\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":15859,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-13160","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nComputer Software Assurance (CSA) | QFINITY<\/title>\n<meta name=\"description\" content=\"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/q-finity.de\/en\/computer-software-assurance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Computer Software Assurance (CSA) | QFINITY\" \/>\n<meta property=\"og:description\" content=\"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/q-finity.de\/en\/computer-software-assurance\/\" \/>\n<meta property=\"og:site_name\" content=\"QFINITY\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T14:52:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/07\/csa-hero-e.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Computer Software Assurance\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\",\"url\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\",\"name\":\"Computer Software Assurance (CSA) | QFINITY\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2026\\/07\\/csa-hero-e.png\",\"datePublished\":\"2024-07-08T17:18:58+00:00\",\"dateModified\":\"2026-08-05T14:52:58+00:00\",\"description\":\"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#primaryimage\",\"url\":\"https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2026\\/07\\/csa-hero-e.png\",\"contentUrl\":\"https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2026\\/07\\/csa-hero-e.png\",\"width\":1024,\"height\":576,\"caption\":\"Computer Software Assurance - risikobasierter FDA-Ansatz f\u00fcr Software in Produktion und QMS von Medizinprodukteherstellern\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/q-finity.de\\\/en\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Computer Software Assurance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/q-finity.de\\\/en\\\/\",\"name\":\"QFINITY\",\"description\":\"Qualit\u00e4tsmanagement & - sicherung\",\"publisher\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/q-finity.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#organization\",\"name\":\"QFINITY\u221e\",\"url\":\"https:\\\/\\\/q-finity.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\/\\/mlsqau6zetur.i.optimole.com\\/cb:frAi.c2d9\\/w:512\\/h:512\\/q:mauto\\/f:best\\/https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2021\\/03\\/cropped-cropped-signet_PAN_orange.png\",\"contentUrl\":\"https:\\/\\/mlsqau6zetur.i.optimole.com\\/cb:frAi.c2d9\\/w:512\\/h:512\\/q:mauto\\/f:best\\/https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2021\\/03\\/cropped-cropped-signet_PAN_orange.png\",\"width\":512,\"height\":512,\"caption\":\"QFINITY\u221e\"},\"image\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/q-finity-quality-management\\\/\",\"https:\\\/\\\/www.instagram.com\\\/qfinity_official\\\/\"],\"founder\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#founder\"}},{\"@type\":\"FAQPage\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#faq\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is CSA mandatory?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. An FDA guidance describes the agency's current thinking; it is not binding. What is binding are the applicable requirements - in the US, since February 2, 2026, the QMSR with the incorporated requirements of ISO 13485:2016. CSA describes a recognized risk-based way to meet them; alternative approaches remain acceptable as long as they satisfy the requirements.\"}},{\"@type\":\"Question\",\"name\":\"Did the FDA invent the risk-based approach?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. In Europe, Annex 11 (first version 1992, in force today as revised in 2011) and Annex 15 (2001, today 2015) tied validation to use, lifecycle and risk before the FDA initiative; PIC\\\/S inspection practice (PI 011, 2003) rated deficiencies by the relative risk of the application. The FDA elevated risk to a guiding principle in 2002-2004, and ICH Q9 systematized it as QRM. CSA is the latest confirmation of that path - not its beginning.\"}},{\"@type\":\"Question\",\"name\":\"Does CSA apply only to medical device manufacturers?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Formally, yes: CSA applies to software in the production and quality management systems of medical device manufacturers - device software itself (design verification and validation) is explicitly outside its scope. Its core - testing effort based on intended use and process risk - follows the same thinking as ICH Q9 and GAMP 5, which serve as methodological orientation industry-wide. That is why CSA carries beyond the device world - though it does not replace the requirements that apply there.\"}},{\"@type\":\"Question\",\"name\":\"What does \\\"Least Burdensome\\\" mean in practice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Least Burdensome does not mean testing or documenting as little as possible. It means not producing more effort and evidence than controlling the identified risk requires - for example: using existing supplier evidence; digital system records instead of redundant screenshots; unscripted testing, including exploratory, where it is better suited; reusing automated tests; focusing your own testing on genuine evidence gaps. Where risk is high, high rigor remains required.\"}}],\"isPartOf\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\"}},{\"@type\":\"Service\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/#service\",\"name\":\"Computer Software Assurance\",\"serviceType\":\"Computer Software Assurance\",\"url\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\",\"areaServed\":[{\"@type\":\"Country\",\"name\":\"Germany\"},{\"@type\":\"Country\",\"name\":\"Austria\"},{\"@type\":\"Country\",\"name\":\"Switzerland\"}],\"description\":\"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.\",\"provider\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#organization\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/computer-software-assurance\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#founder\",\"name\":\"Oliver Herrmann\",\"jobTitle\":\"Founder & CEO\",\"url\":\"https:\\\/\\\/q-finity.de\\\/en\\\/\",\"worksFor\":{\"@id\":\"https:\\\/\\\/q-finity.de\\\/en\\\/#organization\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/olherrmann\\\/\",\"https:\\\/\\\/virtual.ispe.org\\\/b\\\/sp\\\/oliver-herrmann-4399\"],\"knowsAbout\":[\"GxP-Compliance\",\"Computer System Validation\",\"Computer Software Assurance\",\"Data Integrity\",\"ALCOA++\",\"AI Governance\",\"GAMP 5\"],\"image\":\"https:\\/\\/q-finity.de\\/wp-content\\/uploads\\/2026\\/06\\/oliver-herrmann-qfinity-ceo-scaled.jpg\",\"description\":\"Founder and CEO of QFINITY, GAMP Europe Chair, qualified GAMP 5 and GAMP Data Integrity trainer, GQMA auditor and international speaker. Co-author of several ISPE GAMP guides, including the GAMP 5 Guide (2nd Edition).\",\"memberOf\":{\"@type\":\"Organization\",\"name\":\"International Society for Pharmaceutical Engineering (ISPE)\",\"url\":\"https:\\\/\\\/ispe.org\"},\"hasCredential\":[{\"@type\":\"EducationalOccupationalCredential\",\"credentialCategory\":\"degree\",\"name\":\"Graduate Computer Scientist (Dipl.-Inf.)\"},{\"@type\":\"EducationalOccupationalCredential\",\"credentialCategory\":\"certification\",\"name\":\"Microsoft Certified Systems Engineer (MCSE)\"},{\"@type\":\"EducationalOccupationalCredential\",\"credentialCategory\":\"certification\",\"name\":\"SAFe (Scaled Agile Framework)\"}]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Computer Software Assurance (CSA) | QFINITY","description":"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","og_locale":"en_US","og_type":"article","og_title":"Computer Software Assurance (CSA) | QFINITY","og_description":"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.","og_url":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","og_site_name":"QFINITY","article_modified_time":"2026-08-05T14:52:58+00:00","og_image":[{"url":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/07\/csa-hero-e.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"Computer Software Assurance","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","url":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","name":"Computer Software Assurance (CSA) | QFINITY","isPartOf":{"@id":"https:\/\/q-finity.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#primaryimage"},"image":{"@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#primaryimage"},"thumbnailUrl":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/07\/csa-hero-e.png","datePublished":"2024-07-08T17:18:58+00:00","dateModified":"2026-08-05T14:52:58+00:00","description":"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.","breadcrumb":{"@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/q-finity.de\/en\/computer-software-assurance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#primaryimage","url":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/07\/csa-hero-e.png","contentUrl":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/07\/csa-hero-e.png","width":1024,"height":576,"caption":"Computer Software Assurance - risikobasierter FDA-Ansatz f\u00fcr Software in Produktion und QMS von Medizinprodukteherstellern"},{"@type":"BreadcrumbList","@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/q-finity.de\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Computer Software Assurance"}]},{"@type":"WebSite","@id":"https:\/\/q-finity.de\/en\/#website","url":"https:\/\/q-finity.de\/en\/","name":"QFINITY","description":"Qualit\u00e4tsmanagement & - sicherung","publisher":{"@id":"https:\/\/q-finity.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/q-finity.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/q-finity.de\/en\/#organization","name":"QFINITY\u221e","url":"https:\/\/q-finity.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/q-finity.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:frAi.c2d9\/w:512\/h:512\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2021\/03\/cropped-cropped-signet_PAN_orange.png","contentUrl":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:frAi.c2d9\/w:512\/h:512\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2021\/03\/cropped-cropped-signet_PAN_orange.png","width":512,"height":512,"caption":"QFINITY\u221e"},"image":{"@id":"https:\/\/q-finity.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/q-finity-quality-management\/","https:\/\/www.instagram.com\/qfinity_official\/"],"founder":{"@id":"https:\/\/q-finity.de\/en\/#founder"}},{"@type":"FAQPage","@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#faq","mainEntity":[{"@type":"Question","name":"Is CSA mandatory?","acceptedAnswer":{"@type":"Answer","text":"No. An FDA guidance describes the agency's current thinking; it is not binding. What is binding are the applicable requirements - in the US, since February 2, 2026, the QMSR with the incorporated requirements of ISO 13485:2016. CSA describes a recognized risk-based way to meet them; alternative approaches remain acceptable as long as they satisfy the requirements."}},{"@type":"Question","name":"Did the FDA invent the risk-based approach?","acceptedAnswer":{"@type":"Answer","text":"No. In Europe, Annex 11 (first version 1992, in force today as revised in 2011) and Annex 15 (2001, today 2015) tied validation to use, lifecycle and risk before the FDA initiative; PIC\/S inspection practice (PI 011, 2003) rated deficiencies by the relative risk of the application. The FDA elevated risk to a guiding principle in 2002-2004, and ICH Q9 systematized it as QRM. CSA is the latest confirmation of that path - not its beginning."}},{"@type":"Question","name":"Does CSA apply only to medical device manufacturers?","acceptedAnswer":{"@type":"Answer","text":"Formally, yes: CSA applies to software in the production and quality management systems of medical device manufacturers - device software itself (design verification and validation) is explicitly outside its scope. Its core - testing effort based on intended use and process risk - follows the same thinking as ICH Q9 and GAMP 5, which serve as methodological orientation industry-wide. That is why CSA carries beyond the device world - though it does not replace the requirements that apply there."}},{"@type":"Question","name":"What does \"Least Burdensome\" mean in practice?","acceptedAnswer":{"@type":"Answer","text":"Least Burdensome does not mean testing or documenting as little as possible. It means not producing more effort and evidence than controlling the identified risk requires - for example: using existing supplier evidence; digital system records instead of redundant screenshots; unscripted testing, including exploratory, where it is better suited; reusing automated tests; focusing your own testing on genuine evidence gaps. Where risk is high, high rigor remains required."}}],"isPartOf":{"@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/"}},{"@type":"Service","@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/#service","name":"Computer Software Assurance","serviceType":"Computer Software Assurance","url":"https:\/\/q-finity.de\/en\/computer-software-assurance\/","areaServed":[{"@type":"Country","name":"Germany"},{"@type":"Country","name":"Austria"},{"@type":"Country","name":"Switzerland"}],"description":"Computer Software Assurance (CSA): FDA's risk-based approach to software in production and QMS - evidence depth follows intended use and malfunction risk.","provider":{"@id":"https:\/\/q-finity.de\/en\/#organization"},"isPartOf":{"@id":"https:\/\/q-finity.de\/en\/computer-software-assurance\/"}},{"@type":"Person","@id":"https:\/\/q-finity.de\/en\/#founder","name":"Oliver Herrmann","jobTitle":"Founder & CEO","url":"https:\/\/q-finity.de\/en\/","worksFor":{"@id":"https:\/\/q-finity.de\/en\/#organization"},"sameAs":["https:\/\/www.linkedin.com\/in\/olherrmann\/","https:\/\/virtual.ispe.org\/b\/sp\/oliver-herrmann-4399"],"knowsAbout":["GxP-Compliance","Computer System Validation","Computer Software Assurance","Data Integrity","ALCOA++","AI Governance","GAMP 5"],"image":"https:\/\/mlsqau6zetur.i.optimole.com\/cb:mN7M.c4bb\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/q-finity.de\/wp-content\/uploads\/2026\/06\/oliver-herrmann-qfinity-ceo-scaled.jpg","description":"Founder and CEO of QFINITY, GAMP Europe Chair, qualified GAMP 5 and GAMP Data Integrity trainer, GQMA auditor and international speaker. Co-author of several ISPE GAMP guides, including the GAMP 5 Guide (2nd Edition).","memberOf":{"@type":"Organization","name":"International Society for Pharmaceutical Engineering (ISPE)","url":"https:\/\/ispe.org"},"hasCredential":[{"@type":"EducationalOccupationalCredential","credentialCategory":"degree","name":"Graduate Computer Scientist (Dipl.-Inf.)"},{"@type":"EducationalOccupationalCredential","credentialCategory":"certification","name":"Microsoft Certified Systems Engineer (MCSE)"},{"@type":"EducationalOccupationalCredential","credentialCategory":"certification","name":"SAFe (Scaled Agile Framework)"}]}]}},"_links":{"self":[{"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/pages\/13160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/comments?post=13160"}],"version-history":[{"count":17,"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/pages\/13160\/revisions"}],"predecessor-version":[{"id":16371,"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/pages\/13160\/revisions\/16371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/media\/15859"}],"wp:attachment":[{"href":"https:\/\/q-finity.de\/en\/wp-json\/wp\/v2\/media?parent=13160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}